[go: up one dir, main page]

AR073209A1 - Tienopirimidinas utiles para la profilaxis y/o tratamiento de enfermedades influenciadas por la inhibicion de quinasas mnk1 y/o mnk2 ,tales como enfermedades metabolicas y trastornos inflamatorios,y composiciones farmaceuticas que las contienen. - Google Patents

Tienopirimidinas utiles para la profilaxis y/o tratamiento de enfermedades influenciadas por la inhibicion de quinasas mnk1 y/o mnk2 ,tales como enfermedades metabolicas y trastornos inflamatorios,y composiciones farmaceuticas que las contienen.

Info

Publication number
AR073209A1
AR073209A1 ARP090103272A ARP090103272A AR073209A1 AR 073209 A1 AR073209 A1 AR 073209A1 AR P090103272 A ARP090103272 A AR P090103272A AR P090103272 A ARP090103272 A AR P090103272A AR 073209 A1 AR073209 A1 AR 073209A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
heteroatom selected
heterocyclyl
heteroaryl
Prior art date
Application number
ARP090103272A
Other languages
English (en)
Inventor
John Danilewicz
Martin Schneider
Matthias Austen
Phillip Black
Ian Linney
Kay Schreiter
Wesley Blackaby
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40266066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073209(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR073209A1 publication Critical patent/AR073209A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque tiene la formula general (1) en la que X se selecciona entre CH o N; R2 se selecciona entre H, CN, CF3, CON(R4)2; O-alquilo C1-8 opcionalmente sustituido con R3; heterociclilo C3-10 que comprende al menos un heteroátomo seleccionado entre N, S y O; heteroarilo C5-10 que comprende al menos un heteroátomo seleccionado entre N, S y O; y alquilo C1-8 opcionalmente sustituido con R6; y cuando X es CH, R2 también puede ser F, CI, SO2NH2; Y se selecciona entre alquilo C1-8 de cadena lineal o ramificada, opcionalmente sustituido con uno o más de R3; cicloalquilo C3-8, opcionalmente sustituido con uno o más de R9; y sistemas heterocíclicos seleccionados entre una cualquiera de las formulas (2) opcionalmente sustituido con uno o más de R9, donde n es independientemente 1 a 3 U es independientemente O o NR5; R1 se selecciona entre H; CI; y alquilo C1-8, opcionalmente sustituido con N(R4)2 o F; R3 se selecciona entre OH, OR4 y N(R4)2 desde el segundo átomo de carbono de la cadena alquilo al que se une R3 en adelante; F; CO2H; CON(R4)2; SO2N(R4)2; heterociclilo C3-10 que comprende al menos un heteroátomo seleccionado entre N, S y O donde el átomo de nitrogeno puede estar sustituido con H o alquilo C1-3; y heteroarilo C5-10 que comprende al menos un heteroátomo seleccionado entre N, S y O; R4 se selecciona entre H y alquilo C1-8; R5 se selecciona entre H; alquilo C1-8, alquenilo C2-8, cicloalquilo C3 -10; heterociclilo C3-10 que comprende al menos un heteroátomo seleccionado entre N, S y O; heteroarilo C5-10 que comprende al menos un heteroátomo seleccionada entre N, S y O; COR6, CO2R4; CONH(CH2)mR6; (CH2)mR6; CO(CH2)mR6; (CH2)mC(O)R6; SO2R4; y SO2(CH2)mR6; donde m es 1-4; R6 se selecciona entre H; OH; OR4; OC(O)R4; N(R4)2; F; CO2H; CON(R4)2; SO2N(R4)2; heterociclilo que comprende al menos un heteroátomo seleccionado entre N, S y O; y heteroarilo C5-10 que comprende al menos un heteroátomo seleccionado entre N, S y O y que está opcionalmente sustituido con alquilo C1-3 o N(R4)2; W se selecciona entre F; CI; Br; I; CN; -(CH2)1-2NR7R8; -C(S)NH2; -CONR7R8; -C(=NR7)NR7R8; -CO2R7; y -SO2NR7R8; o W junto con R1 puede formar un anillo heterocíclico de cinco o siete miembros que comprende al menos un heteroátomo seleccionado entre N, S y O, donde el átomo de nitrogeno puede estar sustituido con H, -C(O)-O-alquilo C1-4, -CO-(CH2)1-2-NH2, -CO-(CH2)1-2-NH(alquilo C1-3) o -CO-(CH2)1-2-N(alquilo C1-3)2; R7se selecciona entre H y alquilo C1-8; R8 se selecciona entre H; alquilo C1-8 opcionalmente sustituido con R3; heterociclilo C3-10 que comprende al menos un heteroátomo seleccionado entre N, S y O, opcionalmente sustituido con alquilo C1-3, y heteroarilo C5-10 que comprende al menos un heteroátomo seleccionado entre N, S y O; R9 se selecciona entre OH, OR4, N(R4)2, N(R4)COR4, NR4SO2R4 y N(R4)-(CH2)m-R4 sobre cualquier átomo de carbono distinto del unido a O o N; F; CO2H; CON(R4)2; SO2N(R4)2; SO2R4; (CH2)mOR4; (CH2)mN(R4)2; heterociclilo C3-10 que comprende al menos un heteroátomo seleccionado entre N, S y O y heteroarilo C5-10 que comprende al menos un heteroátomo seleccionado entre N, S y O; con la condicion de que se excluya el compuesto 4-(2-metoxifenilamino)-5-metiltieno[2,3-d]pirimidina-6-carboxilato de etilo; o un tautomero, metabolito, profármaco o una al farmacéuticamente aceptable del mismo.
ARP090103272A 2008-08-26 2009-08-25 Tienopirimidinas utiles para la profilaxis y/o tratamiento de enfermedades influenciadas por la inhibicion de quinasas mnk1 y/o mnk2 ,tales como enfermedades metabolicas y trastornos inflamatorios,y composiciones farmaceuticas que las contienen. AR073209A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08015049 2008-08-26

Publications (1)

Publication Number Publication Date
AR073209A1 true AR073209A1 (es) 2010-10-20

Family

ID=40266066

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103272A AR073209A1 (es) 2008-08-26 2009-08-25 Tienopirimidinas utiles para la profilaxis y/o tratamiento de enfermedades influenciadas por la inhibicion de quinasas mnk1 y/o mnk2 ,tales como enfermedades metabolicas y trastornos inflamatorios,y composiciones farmaceuticas que las contienen.

Country Status (18)

Country Link
US (1) US8486953B2 (es)
EP (1) EP2331551B1 (es)
JP (1) JP5675614B2 (es)
KR (1) KR20110045019A (es)
CN (1) CN102186857A (es)
AR (1) AR073209A1 (es)
AU (1) AU2009286734A1 (es)
BR (1) BRPI0918971A2 (es)
CA (1) CA2735361A1 (es)
CL (1) CL2011000409A1 (es)
ES (1) ES2593495T3 (es)
IL (1) IL211008A0 (es)
MX (1) MX2011001938A (es)
NZ (1) NZ591113A (es)
RU (1) RU2011110908A (es)
TW (1) TW201014864A (es)
UY (1) UY32072A (es)
WO (1) WO2010023181A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1899353A1 (en) * 2005-06-22 2008-03-19 DeveloGen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
EA200802118A1 (ru) 2006-04-07 2009-04-28 Девелоджен Ациенгезельшафт Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
NZ591113A (en) 2008-08-26 2012-07-27 Boehringer Ingelheim Int Thienopyrimidine linked to phenyl or pyridine via an nh amine for pharmaceutical compositions
EA201201191A1 (ru) * 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
JP5575275B2 (ja) 2010-02-26 2014-08-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物のための置換アルキル基含有チエノピリミジン
US20130065914A1 (en) * 2010-02-26 2013-03-14 Boehringer Ingelheim International Gmbh Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
MX343138B (es) * 2011-07-29 2016-10-25 K Hansson Göran Terapia de ácido 3-hidroxiantranílico (3-haa) para la prevención y el tratamiento de hiperlipidemia y sus complicaciones cardiovasculares.
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
JP6109193B2 (ja) * 2012-01-10 2017-04-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト チエノピリミジン化合物
US9540392B2 (en) 2012-05-21 2017-01-10 Bayer Pharma Aktiengesellschaft Thienopyrimidines
EP2852595B1 (en) 2012-05-21 2016-06-22 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
EP2917185B1 (en) * 2012-11-09 2017-05-10 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
WO2014118226A1 (en) 2013-02-01 2014-08-07 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
EP2951187A1 (en) 2013-02-01 2015-12-09 Bayer Pharma Aktiengesellschaft Substituted thienopyrimidines and pharmaceutical use thereof
WO2014135480A1 (en) 2013-03-06 2014-09-12 Bayer Pharma Aktiengesellschaft Substituted thiazolopyrimidines
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
US10167296B2 (en) * 2014-05-07 2019-01-01 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
JP2017519737A (ja) * 2014-05-26 2017-07-20 バイエル・ファルマ・アクティエンゲゼルシャフト 置換テトラヒドロピリドチエノピリミジン
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
CA2982984C (en) 2015-04-20 2023-10-17 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
GB201520500D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
WO2017117052A1 (en) 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
NZ796735A (en) 2017-02-06 2025-12-19 Univ Case Western Reserve Compositions and methods of modulating short-chain dehydrogenase activity
EA201991894A1 (ru) * 2017-02-14 2020-02-05 Эффектор Терапьютикс, Инк. ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
FI3802517T3 (fi) 2018-06-07 2023-03-23 Idorsia Pharmaceuticals Ltd Alkoksisubstituoituja pyridinyylijohdannaisia LPA1-reseptoriantagonisteina ja niiden käyttö fibroosin hoidossa
JP2022505846A (ja) 2018-10-24 2022-01-14 イーフェクター セラピューティクス， インコーポレイテッド Ｍｎｋ阻害剤の結晶形態
CN120463720A (zh) 2018-11-21 2025-08-12 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH408945A (de) 1956-02-10 1966-03-15 Ciba Geigy Verfahren zur Herstellung von heterocyclischen Verbindungen
DD248593A1 (de) 1985-01-11 1987-08-12 Univ Halle Wittenberg Verfahren zur herstellung von 4-basischsubstituierten thieno/2,3-d/pyrimidin-6-ylcarbonsaeureestern
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
BR9101256A (pt) 1990-03-30 1991-11-05 Dowelanco Composto,composicao fungicida,processo fungicida,composicao inseticida ou acaricida e processo inseticida ou acaricida
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
EP0682027B1 (de) 1994-05-03 1997-10-15 Novartis AG Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US6395733B1 (en) 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
HUP0100287A3 (en) 1997-11-11 2003-04-28 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US20030162795A1 (en) 1998-10-22 2003-08-28 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
HK1045306A1 (zh) 1999-06-03 2002-11-22 Abbott Laboratories 抑制细胞黏附的抗炎化合物
JP2005503345A (ja) 2001-04-30 2005-02-03 バイエル・コーポレーシヨン 新規な４−アミノ−５，６−置換チオフェノ［２，３−ｄ］ピリミジン
WO2003037362A2 (en) 2001-10-29 2003-05-08 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
ATE389653T1 (de) 2003-05-28 2008-04-15 Univ Siena 4-substituierte derivate von pyrazolo 3,4-d pyrimidin und deren verwendungen
US7521460B2 (en) 2003-06-20 2009-04-21 Ucb Pharma S.A. Thienopyridone derivatives as kinase inhibitors
DE602004003952T2 (de) 2003-07-24 2007-11-08 Bayer Pharmaceuticals Corp., West Haven Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
DK1703902T3 (da) 2004-01-05 2011-02-14 Merz Pharma Gmbh & Co Kgaa Memantin til behandling af mild til moderat Alzheimer's sygdom
JPWO2005080377A1 (ja) 2004-02-20 2007-10-25 キリンホールディングス株式会社 ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
AU2005270068B2 (en) 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
WO2006094791A1 (en) 2005-03-08 2006-09-14 Develogen Aktiengesellschaft Crystallographic structure of mnk-1 and mnk-2 proteins
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
BRPI0610322B8 (pt) 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
EP1899353A1 (en) 2005-06-22 2008-03-19 DeveloGen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
WO2007056215A2 (en) 2005-11-02 2007-05-18 Cytovia, Inc. N-aryl-thienopyrimidin-4-amines and the use thereof
WO2007056214A2 (en) 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof
WO2007059905A2 (en) 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
WO2007084815A2 (en) * 2006-01-19 2007-07-26 Janssen Pharmaceutica, N.V. Substituted thienopyrimidine kinase inhibitors
EA200802118A1 (ru) 2006-04-07 2009-04-28 Девелоджен Ациенгезельшафт Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
ES2340093T3 (es) 2006-06-22 2010-05-28 Biovitrum Ab (Publ) Derivados pirazina y piridina como inhibidores de cinasa mnk.
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
US20100247517A1 (en) 2007-11-22 2010-09-30 Boehringer Ingelheim Internationational GmbH Use of mnk inhibitors for the treatment of alzheimer's disease
EP2239975B1 (en) 2008-01-25 2012-04-25 Sharp Kabushiki Kaisha Mobile station device and program
US20100015708A1 (en) 2008-06-18 2010-01-21 Mdrna, Inc. Ribonucleic acids with non-standard bases and uses thereof
NZ591113A (en) 2008-08-26 2012-07-27 Boehringer Ingelheim Int Thienopyrimidine linked to phenyl or pyridine via an nh amine for pharmaceutical compositions
JP5575275B2 (ja) 2010-02-26 2014-08-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物のための置換アルキル基含有チエノピリミジン
EA201201191A1 (ru) 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
US20130065914A1 (en) 2010-02-26 2013-03-14 Boehringer Ingelheim International Gmbh Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
ES2583015T3 (es) 2011-09-07 2016-09-16 Nordex Energy Gmbh Procedimiento para la fabricación de un componente de pala de rotor de instalación de energía eólica con un larguero principal prefabricado

Also Published As

Publication number Publication date
US8486953B2 (en) 2013-07-16
EP2331551A1 (en) 2011-06-15
CN102186857A (zh) 2011-09-14
KR20110045019A (ko) 2011-05-03
ES2593495T3 (es) 2016-12-09
TW201014864A (en) 2010-04-16
RU2011110908A (ru) 2012-10-10
WO2010023181A1 (en) 2010-03-04
IL211008A0 (en) 2011-04-28
JP2012500825A (ja) 2012-01-12
MX2011001938A (es) 2011-03-29
UY32072A (es) 2010-03-26
CA2735361A1 (en) 2010-03-04
JP5675614B2 (ja) 2015-02-25
BRPI0918971A2 (pt) 2015-12-01
US20120128686A1 (en) 2012-05-24
EP2331551B1 (en) 2016-06-29
NZ591113A (en) 2012-07-27
AU2009286734A1 (en) 2010-03-04
CL2011000409A1 (es) 2011-07-29

Similar Documents

Publication Publication Date Title
AR073209A1 (es) Tienopirimidinas utiles para la profilaxis y/o tratamiento de enfermedades influenciadas por la inhibicion de quinasas mnk1 y/o mnk2 ,tales como enfermedades metabolicas y trastornos inflamatorios,y composiciones farmaceuticas que las contienen.
HN2004000129A (es) Derivados de pirimidina
ES2491140T3 (es) Derivados de flavona enantioméricamente puros para el tratamiento de trastornos proliferativos y procesos para su preparación
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
RU2008114378A (ru) Производные 2-аминопиримидина как модуляторы активности н4-рецептора гистамина
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
AR064965A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
AR084507A1 (es) Derivados de indazoliltriazol
AR055916A1 (es) Derivados de dihidrobenzofurano, usos de los mismos en la preparacion de un medicamento y composicion farmaceutica
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
CR9587A (es) Derivados de piridazina
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
AR043049A1 (es) Derivados de hidantoina, proceso de preparacion del mismo y composicion farmaceutica
AR055395A1 (es) Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CL2011003302A1 (es) Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros.
AR082633A1 (es) Analogos de tetraciclina
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
AR078508A1 (es) Derivados spiro [2.4]heptano puenteados, composiciones farmaceuticas y uso de los mismos
MX2009003410A (es) Fosfoindoles enantiomericamente puros como inhibidores de vih.
EA201100698A1 (ru) Производные тиенотриазолодиазепина, активные в отношении апо а1
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
AR055015A1 (es) Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos.
AR064657A1 (es) 8- alquinilxantinas y derivados
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
AR045082A1 (es) Compuestos de aminobenzofenona y su uso en tratamientos terapeuticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure